Related Experiment Videos
Technology evaluation: HIV ribozyme gene therapy, Gene Shears Pty Ltd
1Gene Shears Pty Ltd, GPO Box 1600, Canberra, ACT 2601, Australia. rdefeyter@pican.pi.csiro.au
Current Opinion in Molecular Therapeutics
|March 16, 2001
Summary
Catalytic RNAs called ribozymes are being developed as therapies for HIV. Hammerhead ribozymes targeting HIV genes showed promise in protecting cells and are now in human safety trials.
Area of Science:
- Biochemistry
- Molecular Biology
- RNA Therapeutics
Background:
- Ribozymes are catalytic RNA molecules with therapeutic potential.
- Hammerhead ribozymes can be designed to target specific disease-related RNA sequences.
- HIV infection poses a significant global health challenge.
Purpose of the Study:
- To develop ribozyme-based therapeutics for HIV infection.
- To target essential HIV genes, such as the tat gene and the Psi packaging sequence, using hammerhead ribozymes.
- To evaluate the efficacy of ribozymes in protecting cells from viral infection.
Main Methods:
- Engineering hammerhead ribozymes to target HIV RNA.
- Expressing ribozyme constructs in hematopoietic cells in culture.
- Conducting Phase I clinical trials to assess safety and feasibility.
Main Results:
- Ribozymes successfully protected hematopoietic cells against HIV infection in vitro.
- The anti-tat ribozyme demonstrated potential therapeutic activity.
- Phase I clinical trials for the anti-tat ribozyme are currently underway.
Conclusions:
- Hammerhead ribozyme technology shows promise as a novel therapeutic strategy against HIV.
- Further clinical evaluation is necessary to establish the safety and efficacy of ribozyme therapy in humans.
- This approach offers a potential new avenue for HIV treatment.